Your browser doesn't support javascript.
Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer.
Maki, Masatoshi; Takada, Ryo; Taniguchi, Akihiko; Nomura, Naoyuki; Kuramoto, Seiichiro; Chiko, Yuki; Okada, Toshiaki; Saito, Seiji; Tamura, Koji.
  • Maki M; Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama, Hiroshima, 720-8520, Japan. maki.masatoshi.zh@mail.hosp.go.jp.
  • Takada R; Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama, Hiroshima, 720-8520, Japan.
  • Taniguchi A; Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Fukuyama, Hiroshima, Japan.
  • Nomura N; Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama, Hiroshima, 720-8520, Japan.
  • Kuramoto S; Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama, Hiroshima, 720-8520, Japan.
  • Chiko Y; Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Fukuyama, Hiroshima, Japan.
  • Okada T; Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center, Fukuyama, Hiroshima, Japan.
  • Saito S; Department of Infection Control, National Hospital Organization Fukuyama Medical Center, Fukuyama, Hiroshima, Japan.
  • Tamura K; Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, Fukuyama, Hiroshima, 720-8520, Japan.
J Pharm Health Care Sci ; 8(1): 27, 2022 Nov 01.
Article in English | MEDLINE | ID: covidwho-2098465
ABSTRACT

BACKGROUND:

COVID-19 has become a significant health threat and a primary healthcare concern among the most vulnerable patients with cancer. Patients with COVID-19 who have lung cancer are at great risk and need careful monitoring if they are affected. This study aimed to investigate the clinical characteristics of COVID-19-positive patients with lung cancer and the risks associated with anticancer medication.

METHODS:

This study was a single-center, retrospective cohort study. Patients with lung cancer who presented with COVID-19 during hospitalization were divided into two groups those who presented with respiratory failure and those who did not. The patient's background, clinical laboratory values, and anticancer drugs used for therapy were investigated to identify risk factors for respiratory failure.

RESULTS:

Thirty-one patients were included in the study; 18 (58.1%) were in the respiratory failure group and 13 (41.9%) were in the group without respiratory failure. In the respiratory failure group, there was a significant difference in using immune checkpoint inhibitor (ICI) use within 90 days (p = 0.025) and the level of C-reactive protein (CRP) level (p = 0.017). The analysis of the operating characteristic of the receiver revealed a cutoff value of 2.75 mg/dL for CRP (area under the curve = 0.744, sensitivity 0.611, specificity 0.923).

CONCLUSIONS:

A history of ICI within 90 days and elevated CRP (≥ 2.75 mg/dL) levels are potential factors leading to respiratory failure in COVID-19-affected patients undergoing chemotherapy for lung cancer.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Pharm Health Care Sci Year: 2022 Document Type: Article Affiliation country: S40780-022-00259-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: J Pharm Health Care Sci Year: 2022 Document Type: Article Affiliation country: S40780-022-00259-6